In vivo effects of two novel alkylating benzodiazepines, irazepine and kenazepine.
Intracerebroventricular administration of the alkylating benzodiazepines irazepine or kenazepine (20 nmol) resulted in a complete protection against convulsant doses of pentylenetetrazole (PTZ) for at least one hour, and a statistically significant protection for at least two and four hours, respectively. In contrast, administration of the non-alkylating parent benzodiazepine Ro-7/1986 or diazepam (20-60 nmol) resulted in no detectable anticonvulsants effects at fifteen minutes post-injection, the earliest interval examined. These results suggest that alkylating benzodiazepines which bind to brain benzodiazepine receptors in a non-competitive (covalent) fashion in vitro may exert a long lasting anticonvulsants effect by a similar mechanism.
D000818:Animals; D000927:Anticonvulsants; D001570:Benzodiazepinones / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D003975:Diazepam / Q000378:metabolism; D051379:Mice; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors
D000927:Anticonvulsants; D001570:Benzodiazepinones; C019439:irazepine; C028261:kenazepine; D003975:Diazepam; D010433:Pentylenetetrazole